Characterization of genetic aberrations in acute myeloid leukemia (AML) has substantially improved our understanding of the pathogenesis of this disease and is of growing importance for more efficient risk assessment for individual patients; however, despite relevant advances, the relapse risk for these patients is high. 1 Effective risk stratification is especially difficult for patients with normal karyotype, who constitute the single largest cytogenetic group of AML. The presence or absence of mutations in the FLT3, MLL, CEBPA and NPM1 genes and/or overexpression of WT1, BAALC or EVI1 are useful markers to predict the clinical outcome of the subgroup with normal cytogenetics, and some of these markers provide potential targets for molecular therapies. However, more studies are necessary to predict the risk in individual patients.
The activating V617F mutation of JAK2 tyrosine kinase has been detected in the majority of patients with polycythemia vera, and in a significant proportion of patients with essential thrombocythemia and idiopathic myelofibrosis, 2 all disorders that can evolve into AML. The same mutation was also found in a small number of patients with either AML or myelodysplastic syndrome (MDS). At present, analysis of patients with AML has identified JAK2-V617F mutations in 51 cases (4.7%), 27 of whom had a preceding myeloproliferative disorder (MPD). [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] However, apart from the group of AML with pre-existing MPD, where the incidence seems to be higher than 60% (27/41), there are few data concerning the frequency of JAK2-V617F in specific subtypes of AML and its association with other biological parameters, since only four articles include the characteristics of the total patient cohort analyzed. 5, [7] [8] [9] Moreover, whether they influence prognosis in patients with AML has not been determined. To further clarify the biological and prognostic impact of the activating tyrosine kinase JAK2 mutation V617F in AML, we investigated its prevalence in a large number of well-characterized AML patients, correlated the results to French-American-British (FAB) classification and WHO (World Health Organization) diagnostic classification, cytogenetics and other molecular markers, and studied the prognostic relevance of this mutation.
Ten cell lines (HEL, EOL-1, CMK, KG-1, F-36P, MEG-01, NOMO-1, Kasumi-4, OCI-AML2 and MUTZ-3) and bone marrow (BM) samples of 339 patients with AML, referred for analysis to the University of Navarra (Spain), were included in the present report. Clinical and hematological characteristics of the samples are included in Table 1 . Only seven were childhood patients (5-18 years of age), all with de novo AML. Although patients were treated with different schedules, all received regimes based on anthracycline and cytarabine, as induction therapy. High-dose cytarabine, and autologous or allogenic stem cell transplantation when possible were used as consolidation therapy. Patients with acute promyelocytic leukemia were treated following the cooperative Spanish PETHEMA PML protocol. Complete remission (CR) was defined as the achievement of a morphologically normal marrow, a granulocyte count of 1.5 Â 10 9 /l or greater and platelet counts of at least 100 Â 10 9 /l. Overall survival (OS) was defined as the time from the day of diagnosis to death or last visit. All patients provided informed consent. Information was collected on clinical and other parameters at diagnosis, and survival during follow-up. Screening of the 339 samples with AML at diagnosis for JAK2-V617F detected 11 cases that were positive for the mutation, giving an overall frequency of the mutation of 3.2%, consistent with previous studies. 7, 9 All mutated patients had either M1 or 7, 9 In our series, the V617F mutation was more frequent in secondary AML (sAML) (8.3%) than in de novo AML (2.7%). Although we only analyzed four patients with M7, we did not find JAK2-V617F in these cases; Jelinek et al. (2005) found the mutation in 2 out of 11 AML-M7 patients and Steensma et al. (2006) in 1 out of 24, suggesting that it would be interesting to analyze a larger group of patients with megakaryocytic leukemia in order to know the real prevalence in this subgroup. 5, 9 Most mutations were heterozygous, but we found a homozygous mutation in one sample at diagnosis (case 8), and in the HEL cell line. A detailed summary of the mutated cases is shown in Table 3 . There was no apparent relationship between sex and the JAK2-V617F (54.5% male vs 45.5% female patients); the median age of these patients was 68 years, and most patients were 460 years, but the range was 25-82 years. There was no evidence of erythroid lineage proliferation in the BM of the patients with JAK2 mutation. All cases mutated exhibited anemia and thrombocytopenia, features that mice transduced with a retrovirus expressing JAK2-V617F have after 3-4 months and that mimic human polycythemia vera and its evolution toward myelofibrosis. 13 Few published works address the relationship between JAK2 mutation and karyotype in AML. Cases were categorized according to the chromosomal abnormalities present in the G-band karyotype in three cytogenetic risk groups (Table 1) . We only found JAK2 mutations in the cytogenetic subgroups with t(8;21) AML1/ETO, inv(16) CBFA/MYH11 and in nine cases included in the intermediate group. Cases with normal karyotype represent more than 40% of all AML and constitute a therapeutic challenge. Preliminary results, and the fact that there are no data about the prevalence of this mutation in this subgroup, led us to analyze 177 cases with normal karyotype, and we found seven cases with the V617F mutation (3.9%). Interestingly, when we took into account cases with AML-M2 and normal karyotype, the incidence was 10.8% (5/46). To further characterize the AML-M2 cases, we analyzed exons 8 and 17 of the KIT gene in the 80 samples in which we had material left. We only found mutations of the exon 17 of KIT in three cases with t(8;21) (3/14, 21.4%), as previously reported. Case 9, a 25-year-old man with AML with t(8;21), had both JAK2-V617F and KIT-D816V, like the two cases reported by Lee et al. (2006) . 7 In eight samples with no JAK2 mutation, we found the same synonymous mutation: N ¼ T/C codon 798 Isoleucine. Although this seems to be a polymorphism with no pathogenic effect, this nucleotide substitution is not yet included in the public single-nucleotide polymorphism (SNP) databases (NCBI and HapMap project).
To further characterize the cases, we analyzed the presence of mutations and quantified the expression of specific genes with impact on the outcome of AML. Our results are similar to other series. Taking together the data of all cases analyzed, 22.1% had FLT3 mutations, 3.2% JAK2, 51.4% NPM1 and 3.7% KIT mutations; three patients had JAK2 and FLT3, JAK2 and KIT or JAK2 and NPM1, and 14 cases had both NPM1 and FLT3 mutations. Considering only cases with normal karyotype, the prevalence was as follows: 29.9% FLT3 mutations, 3.9% JAK2 and 54.6% NPM1. Only case 7, a 68-year-old man with sAML and a normal karyotype, had JAK2-V617F and ITD-FLT3, which shows that in some cases two mutations in TK genes could collaborate in the AML transformation. FLT3 mutations were not found in the other cases, indicating that in most cases these mutations are exclusive, although FLT3-D835 was detected in the relapse of a young woman with AML-M2 de novo (case 4). Although activating mutations of FLT3 are frequent in AML cases and few mutations in the tyrosine kinase c-KIT have also been detected (less than 5%), to find mutations in two different tyrosine kinases in an individual patient, as we detected in cases 7 and 9, is a rare exception (Table 2) . 1 The molecular characterization by real-time PCR of 185 AML samples showed WT1 overexpression (OE) in 76.7% cases (71.7% with normal karyotype), and EVI1 OE in eight of all AML cases (4.3%) and in three cases with normal karyotype (2.8%). In patients with JAK2-V617F at diagnosis, we compared the mutation status in CR and at relapse (Table 3) . JAK2 mutation was not constant through the evolution of the disease. In most cases, the mutation disappeared in CR and appeared again when the patient relapsed, but with exceptions: we detected the mutation in CR in cases 7 and 8, although in case 8 the abnormal karyotype at diagnosis was normal in CR. Moreover, in case 9, a 25-year-old man with t(8;21), we did not detect mutation either in CR or in relapse, although the clone with t(8;21) reappeared in relapse. Therefore, we could conclude that JAK2-V617F mutation is not a good Letters to the Editor Letters to the Editor marker for follow-up control, and these data also could suggest that this mutation does not have a leading role in the AML transformation.
We analyzed the influence of the JAK2-V617F mutation on prognosis, and we found that this mutation has no significant impact on the OS of patients with AML. OS was determined according to the Kaplan-Meier method, and multivariate survival analysis was performed using Cox proportional hazards techniques (SPSS, version 12.0). As expected, in 200 patients with AML at diagnosis for whom clinical follow-up data were available, significant differences in age, CR rate and cytogenetic group were found (Po0.001) (data not shown). When comparing patients who were V617F positive and negative, we found no difference with regard to CR rate (JAK2 mut 63.6% vs JAK2 wt 53.6%; P ¼ 0.553) or to OS (median JAK2 mut 18 vs JAK2 wt 9 months; P ¼ 0.396). In the OS of the subgroup with normal karyotype, we confirmed that FLT3 mutation predicts poor survival in AML patients (P ¼ 0.049); but we found no statistically significant impact of JAK2 mutation in this subgroup either (P ¼ 0.781). The small number of mutated cases did not permit the comparison between other clinical and genetic features. As shown in Table 3 , there was heterogeneity in the outcome of the mutated cases: the median OS of the patients was 18 months, ranging from a few days to 60 months. A detailed analysis shows that the poor outcome depends on other variables with a well-known prognostic impact on AML, such as the age of the patient, the dysplastic features of the sAML, the presence of FLT3-ITD and the karyotype. The three patients with sAML had the worst outcome in the group with JAK2-V617F: they did not respond to induction chemotherapy, two patients died in a few days (cases 3 and 5) and case 7 in 11 months (Table 3) . Genetic evidence in vivo and studies on proliferation and phosphorylation in vitro indicate that the V617F mutation confers a proliferative and survival advantage. 14 Patients with MPD carrying the V617F mutation had significantly poorer survival, and more complications, 15, 16 suggesting a possible poor prognosis in AML patients with this mutation. However, in our series, the poor outcome of the patients with JAK2 mutation seems to depend on other features with a prognostic meaning in AML, such as the myelodysplastic features. These data could suggest that this mutation is an additional genetic event in some patients with AML that contributes to the myeloid proliferation by diverse mechanisms, 9,14 but has no impact on the evolution of the disease. This agrees with a recent report showing that JAK2-V617F mutation represents a genetic defect occurring later in the progression of the disease in MPD. 17 Moreover, the incidence of JAK2-V617F was similar in the favorable (4.4%) and in the intermediate cytogenetic prognostic group (3.8%), and we detected no mutation in the poor prognostic subgroup.
The high prevalence of cases with JAK2 mutation and normal karyotype led us to use the GeneChip Mapping 50 K Xba 240 array (Affymetrix Inc., Santa Clara, CA, USA) to type DNA from nine AML cases with JAK2-V617F and nine cases not mutated from the same subtype to check if the number of cryptic genomic aberrations in the two groups was different. Moreover, we wanted to investigate if the mechanism of the homozygous mutation in case 8 was loss of heterozygosity (LOH) by uniparental disomy (UPD). 18 Copy number estimations were determined by processing the CHP file output of each sample with the Copy Number Analysis Tool (CNAT, version 3.0, Affymetrix) and with the dChipSNP software. 19 We took into consideration aberrations detected by the two software tools. Several abnormalities were detected that were not seen in the karyotype: six duplications and five deletions. Although it is not possible to conclude anything due to the small size of the series, we found more cases with changes in the JAK2-mutated group (69 vs 31%). In 38% of the cases (7/18), we observed large unexpected regions of LOH by UPD. The SNP signal values were indicative of two copies, and this was confirmed by fluorescence in situ hybridization. This approach allowed us to confirm that in case 8 and in the HEL cell line, 9pLOH caused by mitotic recombination is responsible for the transition from heterozygous to homozygous JAK2 V617F, as previously described in some MPD cases, as well as in the HEL cell line. In case 8, who had trisomy 10 at diagnosis, the karyotype concurred with the SNP array results, and we detected LOH by UPD on 9p21-p24, 9q21-9q34 and 8q13-8q21. In CR, the karyotype was normal, and there was a heterozygous mutation that persisted when the patient relapsed with a different clone ( Table 3 ).
In conclusion, our results in a large cohort of wellcharacterized AML cases confirm and extend other studies by showing that the prevalence of JAK2-V617F in de novo AML is low, around 3%, and that this mutation has no impact on the prognosis of patients with this disease. The role of JAK2-V617F in AML is not clear; we investigated its frequency in specific subtypes of AML, focusing on patients with normal karyotype, and its association with biological parameters with a prognostic value in AML, including other TK genes. We identified an acquired JAK2 mutation in 10.8% of patients with AML-M2 and a normal karyotype. Interestingly, two patients had mutations in two different TK genes. The data presented in our study confirm the association of KIT-D816 mutations and t(8;21), whereas mutations of JAK2 and FLT3 were more frequent in samples with normal karyotype. Normal karyotype AML is a heterogeneous group with different molecular mutations, and a better subclassification of this group may be needed to work out a potential prognostic impact of TK mutations. Our data also suggest that JAK2-V617F mutation is not an important molecular prognostic marker for AML. There were no significant differences in the OS of the V617F-positive and V617F-negative groups, and we found substantial inter-individual variations in the outcome and clinical features of the patients with AML and JAK2-V617F, suggesting that the OS of patients with JAK2 mutation is due to other wellknown prognostic parameters in AML. Therefore, this mutation seems to be an additional genetic event in the transformation of patients with AML that contributes to myeloid proliferation, but has no impact on the course of the disease.
Acknowledgements
This work was supported by the Fundació n Científica de la Asociació n Españ ola contra el Cáncer, Ministerio de Educació n y Ciencia (SAF2005/06425), ISCIII-RETIC RD06/0020 and Fundació n para la Investigació n Médica Aplicada y UTE (Spain). We thank María J Larrayoz for technical assistance, José L Vizmanos for useful discussion and Marta García-Granero for statistical support. The phosphatidylinositol-3-kinase-Akt (PI3K-Akt) signalling pathway plays a critical role in regulating the cellular processes of growth, survival and differentiation. Constitutive activation of the pathway is recognized to be heavily implicated in the development of cancer. Mutation of members of the PI3K-Akt pathway is observed in up to 30% of all human cancers, and the PI3K-Akt pathway is constitutively active in primary acute myeloid leukaemia (AML) cells. Furthermore, constitutive Akt phosphorylation is linked to drug resistance and shortened overall survival in AML. Appropriate and timely negative regulation of the PI3K pathway is required to avoid constitutive signalling. SH2-containing inositol 5 0 -phosphatase 1 (SHIP1) is a 145-kDa protein whose expression is restricted to haematopoietic cells. SHIP1 functions as a negative regulator of the PI3K--Akt pathway by hydrolysis of PIP 3 to PI-3,4-P 2 , and it may also play a significant role in regulating Akt membrane localization. Restoration of SHIP1 function to a human T-cell leukaemia cell line downregulates constitutively active Akt and causes delayed cellular transit through the G 1 phase of the cell cycle, restricting cell growth. SHIP1 levels are reduced in primary cells from CML patients and following induction of BCR-ABL. The SHIP1 knockout (À/À) mouse has a shortened lifespan and overproduces granulocytes and macrophages due to hyper-responsiveness of granulocyte/macrophage progenitors to a number of growth factors and cytokines. SHIP1 À/À mice suffer from splenomegaly and extramedullary haematopoiesis, and die from massive myeloid infiltration of the lungs. 1 Together, these findings indicate that the reduction or inactivity of SHIP1 may directly contribute to leukaemia pathogenesis. A single somatic missense phosphatase-domain mutation in INPP5D, the SHIP1 gene, was reported in 1 of 30 AML patients that reduced catalytic activity of SHIP1, 2 and a further seven missense INPP5D mutations were reported in 7 of 32 (22%) Chinese AML patients 3 ( Figure 1 ). These results suggest that SHIP1 mutations may contribute to the pathogenesis of AML, and thus also provide a novel therapeutic target.
We aimed to determine the incidence of INPP5D mutations in a cohort of 57 Caucasian AML patients, representing all eight French-American-British (FAB) subtypes (M0-M7), by denaturing high-performance liquid chromatography (DHPLC) and DNA sequencing. At the outset of our study, we noted that human INPP5D was poorly characterized in the literature and on genome databases. We therefore interpreted INPP5D gene structure based on alignment between INPP5D transcript (cDNA accession U57650) and human chromosome 2 assembled
